S. Gail Eckhardt, MD, Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
S. Gail Eckhardt, MD, Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
Eckhardt says the wnt pathway is highly mutated in colorectal cancer and has been linked to the regulation of the adenomatous polyposis coli (APC) gene and stem cells.
In addition to being a target to treat colorectal cancer, Echkardt says, the wnt pathway is also an area of interest in pancreatic cancer because of the stem cell component.
As the wnt pathway is redundant and complex, Eckhardt says, a combination approach could be most beneficial.
In pancreatic cancer, chemotherapy would be used to de-bulk a tumor before a stem cell targeted wnt inhibitor is administered, Eckhardt says. In colorectal cancer, the MEK pathway and the wnt pathway are both targeted.
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More